1. Market Research
  2. > Healthcare
  3. > Blood Supply, Tissue Banking and Transplantation Market Trends
  4. > Transplantation - Pipeline Review, H2 2013

Transplantation - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 519 pages

Transplantation - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Transplantation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transplantation. Transplantation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Transplantation.
- A review of the Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Transplantation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Transplantation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Transplantation - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
Introduction 7
Transplantation Overview 8
Therapeutics Development 9
Transplantation Therapeutics under Development by Companies 11
Transplantation Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Mid Clinical Stage Products 23
Early Clinical Stage Products 24
Discovery and Pre-Clinical Stage Products 25
Transplantation Therapeutics - Products under Development by Companies 26
Transplantation Therapeutics - Products under Investigation by Universities/Institutes 36
Companies Involved in Transplantation Therapeutics Development 37
Transplantation - Therapeutics Assessment 140
Drug Profiles 148
Transplantation Therapeutics - Drug Profile Updates 382
Transplantation Therapeutics - Discontinued Products 482
Transplantation Therapeutics - Dormant Products 483
Transplantation - Product Development Milestones 490
Appendix 500



List of Tables

Number of Products Under Development for Transplantation, H2 2013 27
Products under Development for Transplantation - Comparative Analysis, H2 2013 28
Number of Products under Development by Companies, H2 2013 30
Number of Products under Development by Companies, H2 2013 (Contd..1) 31
Number of Products under Development by Companies, H2 2013 (Contd..2) 32
Number of Products under Development by Companies, H2 2013 (Contd..3) 33
Number of Products under Development by Companies, H2 2013 (Contd..4) 34
Number of Products under Development by Companies, H2 2013 (Contd..5) 35
Number of Products under Development by Companies, H2 2013 (Contd..6) 36
Number of Products under Development by Companies, H2 2013 (Contd..7) 37
Number of Products under Investigation by Universities/Institutes, H2 2013 39
Comparative Analysis by Late Stage Development, H2 2013 40
Comparative Analysis by Mid Clinical Stage Development, H2 2013 41
Comparative Analysis by Early Clinical Stage Development, H2 2013 42
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 43
Products under Development by Companies, H2 2013 44
Products under Development by Companies, H2 2013 (Contd..1) 45
Products under Development by Companies, H2 2013 (Contd..2) 46
Products under Development by Companies, H2 2013 (Contd..3) 47
Products under Development by Companies, H2 2013 (Contd..4) 48
Products under Development by Companies, H2 2013 (Contd..5) 49
Products under Development by Companies, H2 2013 (Contd..6) 50
Products under Development by Companies, H2 2013 (Contd..7) 51
Products under Development by Companies, H2 2013 (Contd..8) 52
Products under Development by Companies, H2 2013 (Contd..9) 53
Products under Investigation by Universities/Institutes, H2 2013 54
Hospira, Inc., H2 2013 55
F. Hoffmann-La Roche Ltd., H2 2013 56
Kyowa Hakko Kirin Co., Ltd., H2 2013 57
Osiris Therapeutics, Inc., H2 2013 58
Athersys, Inc., H2 2013 59
GlaxoSmithKline plc, H2 2013 60
Quark Pharmaceuticals, Inc., H2 2013 61
Merck and Co., Inc., H2 2013 62
AbGenomics International, Inc., H2 2013 63
Emergent BioSolutions Inc., H2 2013 64
Oxford BioMedica plc, H2 2013 65
Pharming Group N.V., H2 2013 66
Vectura Group plc, H2 2013 67
BioLineRx, Ltd., H2 2013 68
Novartis AG, H2 2013 69
Isotechnika Pharma Inc., H2 2013 70
Samyang Corporation, H2 2013 71
Astellas Pharma Inc., H2 2013 72
ViroPharma Incorporated, H2 2013 73
Cell Therapeutics, Inc., H2 2013 74
Genmab A/S, H2 2013 75
Exelixis, Inc., H2 2013 76
4SC AG, H2 2013 77
Celldex Therapeutics, Inc., H2 2013 78
IMMUNOMEDICS, INC, H2 2013 79
Antisense Therapeutics Limited, H2 2013 80
LifeCycle Pharma A/S, H2 2013 81
Mesoblast Ltd, H2 2013 82
Biovitrum AB, H2 2013 83
NPS Pharmaceuticals, Inc., H2 2013 84
Circadian Technologies Limited, H2 2013 85
Cleveland BioLabs, Inc., H2 2013 86
Accentia Biopharmaceuticals, Inc., H2 2013 87
La Jolla Pharmaceutical Company, H2 2013 88
Jazz Pharmaceuticals, Inc., H2 2013 89
Alexion Pharmaceuticals, Inc., H2 2013 90
Portola Pharmaceuticals, Inc., H2 2013 91
Cerimon Pharmaceuticals, Inc., H2 2013 92
Soligenix, Inc., H2 2013 93
NeoStem, Inc., H2 2013 94
JCR Pharmaceuticals Co., Ltd., H2 2013 95
Pluristem Therapeutics Inc., H2 2013 96
Synta Pharmaceuticals Corp., H2 2013 97
MediPost Co., Ltd., H2 2013 98
Hansa Medical AB, H2 2013 99
Proteo, Inc., H2 2013 100
Cellerant Therapeutics, Inc., H2 2013 101
Digna Biotech, S.L., H2 2013 102
Spectrum Pharmaceuticals, Inc., H2 2013 103
Viron Therapeutics, Inc., H2 2013 104
Palau Pharma S.A, H2 2013 105
Actinium Pharmaceuticals, Inc., H2 2013 106
Pharmagenesis, Inc., H2 2013 107
Pharmalink AB, H2 2013 108
Wellstat Therapeutics Corporation, H2 2013 109
Argos Therapeutics, Inc., H2 2013 110
APT Pharmaceuticals, Inc., H2 2013 111
Alder Biopharmaceuticals Inc., H2 2013 112
Gene Signal International SA., H2 2013 113
ApoImmune, Inc., H2 2013 114
Recoly N.V., H2 2013 115
Opsona Therapeutics Ltd., H2 2013 116
TetraLogic Pharmaceuticals, H2 2013 117
Conatus Pharmaceuticals Inc., H2 2013 118
MSM Protein Technologies, Inc., H2 2013 119
Angion Biomedica Corp., H2 2013 120
NovImmune SA, H2 2013 121
TcL Pharma SAS, H2 2013 122
Polyphor Ltd., H2 2013 123
Omeros Corporation, H2 2013 124
iBio, Inc., H2 2013 125
Kiadis Pharma B.V., H2 2013 126
CG Therapeutics, Inc., H2 2013 127
Bellicum Pharmaceuticals, Inc., H2 2013 128
Sirnaomics, Inc., H2 2013 129
USV Limited., H2 2013 130
Limerick BioPharma, Inc., H2 2013 131
KYORIN Pharmaceutical Co., Ltd., H2 2013 132
Tolera Therapeutics, Inc., H2 2013 133
TaiGen Biotechnology Co., Ltd., H2 2013 134
Medistem, Inc., H2 2013 135
KAHR medical Ltd., H2 2013 136
Medestea Research and Production S.p.A., H2 2013 137
NasVax Ltd., H2 2013 138
Ikaria Inc., H2 2013 139
REGiMMUNE Corporation, H2 2013 140
ADIENNE Pharma and Biotech, H2 2013 141
TikoMed AB, H2 2013 142
Nephrx Corporation, H2 2013 143
Dr. Falk Pharma GmbH, H2 2013 144
Dompe Farmaceutici S.p.A., H2 2013 145
AIMM Therapeutics B.V., H2 2013 146
Amplimmune, Inc., H2 2013 147
Lycera Corp., H2 2013 148
Bio Sidus S.A., H2 2013 149
Icon Bioscience, Inc., H2 2013 150
Therapure Biopharma Inc., H2 2013 151
FCB-Pharmicell Co.,Ltd., H2 2013 152
iTherX Pharmaceuticals Inc., H2 2013 153
ToleroTech Inc., H2 2013 154
CellAct Pharma GmbH, H2 2013 155
Sigmoid Pharma., H2 2013 156
America Stem Cell, Inc., H2 2013 157
Assessment by Monotherapy Products, H2 2013 158
Assessment by Combination Products, H2 2013 159
Assessment by Stage and Route of Administration, H2 2013 162
Assessment by Stage and Molecule Type, H2 2013 165
Transplantation Therapeutics - Drug Profile Updates 400
Transplantation Therapeutics - Discontinued Products 500
Transplantation Therapeutics - Dormant Products 501
Transplantation Therapeutics - Dormant Products (Contd..1) 502
Transplantation Therapeutics - Dormant Products (Contd..2) 503
Transplantation Therapeutics - Dormant Products (Contd..3) 504
Transplantation Therapeutics - Dormant Products (Contd..4) 505
Transplantation Therapeutics - Dormant Products (Contd..5) 506
Transplantation Therapeutics - Dormant Products (Contd..6) 507



List of Figures

Number of Products under Development for Transplantation, H2 2013 27
Products under Development for Transplantation - Comparative Analysis, H2 2013 28
Products under Development by Companies, H2 2013 29
Products under Investigation by Universities/Institutes, H2 2013 38
Late Stage Products, H2 2013 40
Mid Clinical Stage Products, H2 2013 41
Early Clinical Stage Products, H2 2013 42
Discovery and Pre-Clinical Stage Products, H2 2013 43
Assessment by Monotherapy Products, H2 2013 158
Assessment by Combination Products, H2 2013 159
Assessment by Route of Administration, H2 2013 160
Assessment by Stage and Route of Administration, H2 2013 161
Assessment by Molecule Type, H2 2013 163
Assessment by Stage and Molecule Type, H2 2013 164



Companies Mentioned

Hospira, Inc.
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Osiris Therapeutics, Inc.
Athersys, Inc.
GlaxoSmithKline plc
Quark Pharmaceuticals, Inc.
Merck and Co., Inc.
AbGenomics International, Inc.
Emergent BioSolutions Inc.
Oxford BioMedica plc
Pharming Group N.V.
Vectura Group plc
BioLineRx, Ltd.
Novartis AG
Isotechnika Pharma Inc.
Samyang Corporation
Astellas Pharma Inc.
ViroPharma Incorporated
Cell Therapeutics, Inc.
Genmab A/S
Exelixis, Inc.
4SC AG
Celldex Therapeutics, Inc.
IMMUNOMEDICS, INC
Antisense Therapeutics Limited
LifeCycle Pharma A/S
Mesoblast Ltd
Biovitrum AB
NPS Pharmaceuticals, Inc.
Circadian Technologies Limited
Cleveland BioLabs, Inc.
Accentia Biopharmaceuticals, Inc.
La Jolla Pharmaceutical Company
Jazz Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc.
Soligenix, Inc.
NeoStem, Inc.
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Synta Pharmaceuticals Corp.
MediPost Co., Ltd.
Hansa Medical AB
Proteo, Inc.
Cellerant Therapeutics, Inc.
Digna Biotech, S.L.
Spectrum Pharmaceuticals, Inc.
Viron Therapeutics, Inc.
Palau Pharma S.A
Actinium Pharmaceuticals, Inc.
Pharmagenesis, Inc.
Pharmalink AB
Wellstat Therapeutics Corporation
Argos Therapeutics, Inc.
APT Pharmaceuticals, Inc.
Alder Biopharmaceuticals Inc.
Gene Signal International SA.
ApoImmune, Inc.
Recoly N.V.
Opsona Therapeutics Ltd.
TetraLogic Pharmaceuticals
Conatus Pharmaceuticals Inc.
MSM Protein Technologies, Inc.
Angion Biomedica Corp.
NovImmune SA
TcL Pharma SAS
Polyphor Ltd.
Omeros Corporation
iBio, Inc.
Kiadis Pharma B.V.
CG Therapeutics, Inc.
Bellicum Pharmaceuticals, Inc.
Sirnaomics, Inc.
USV Limited.
Limerick BioPharma, Inc.
KYORIN Pharmaceutical Co., Ltd.
Tolera Therapeutics, Inc.
TaiGen Biotechnology Co., Ltd.
Medistem, Inc.
KAHR medical Ltd.
Medestea Research and Production S.p.A.
NasVax Ltd.
Ikaria Inc.
REGiMMUNE Corporation
ADIENNE Pharma and Biotech
TikoMed AB
Nephrx Corporation
Dr. Falk Pharma GmbH
Dompe Farmaceutici S.p.A.
AIMM Therapeutics B.V.
Amplimmune, Inc.
Lycera Corp.
Bio Sidus S.A.
Icon Bioscience, Inc.
Therapure Biopharma Inc.
FCB-Pharmicell Co.,Ltd.
iTherX Pharmaceuticals Inc.
ToleroTech Inc.
CellAct Pharma GmbH
Sigmoid Pharma.
America Stem Cell, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tissue Banking Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2024

Tissue Banking Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Global Tissue Banking Market: Overview Tissue Banking devices are used to store tissues in controlled environment for quality, safety and effective use in different disease treatment. The report on global ...

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises ...

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

Plasma Fractionation Market by Product, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021, to reach USD 26.07 billion by 2021 from USD 18.84 billion in 2016. Growth in this market is mainly attributed ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.